Renal Cell Carcinoma and End Stage Renal Disease

Farivar-Mohseni, Hesam; Perlmutter, Adam E.; Wilson, Shandra; Shingleton, W. Bruce; Bigler, Steven A.; Fowler, Jackson E.

doi:10.1016/s0022-5347(06)00340-5

Cited by 68 publications

(46 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[83][84][85] From 852 patients with end-stage renal disease studied prospectively from 1994 to 2000, 85 19 had clinical evidence of renal neoplasia. Seventeen of these patients underwent nephrectomy with 14 being subsequently diagnosed with renal cell carcinoma, giving a prevalence of 1.64%.…”

Section: Carcinoma Associated With End-stage Renal Diseasementioning

confidence: 99%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma. Clear cell, papillary and chromophobe carcinomas account for 85-90% carcinomas seen in routine practice. The remaining 10-15% of carcinomas consist of rare sporadic and hereditary tumors, some of which had been long recognized, but many of which only emerged as distinct entities in the decade leading up to the WHO publication. Collecting-duct carcinoma is a rare, often lethal form of carcinoma. Medullary carcinoma associated with sickle cell trait, has emerged as a distinctive tumor showing some overlapping features with upper tract urothelial carcinoma. Mucinous tubular and spindle-cell carcinoma and tubulocystic carcinoma were earlier considered as patterns of low-grade collecting-duct carcinoma, but are now recognized as separate tumor entities. Carcinomas associated with somatic translocations of TFE3 and TFEB comprise a significant proportion of pediatric renal carcinomas. Oncocytoid renal carcinomas in neuroblastoma survivors was recognized as a unique tumor category in the WHO classification. Renal carcinoma associated with end-stage renal disease is now recognized as having distinct morphological patterns and behavior. In addition there is a group of rare recently described carcinomas, including clear cell papillary carcinoma, oncocytic papillary renal cell carcinoma, follicular renal carcinoma and leiomyomatous renal cell carcinoma. It behooves the surgical pathologist to not only be capable of diagnosing the common forms of renal cancer, but also to be aware of the rare types of renal carcinoma, many of which have emerged in recent years.

show abstract

Section: Carcinoma Associated With End-stage Renal Diseasementioning

confidence: 99%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

show abstract

“…In addition to traditional cancer risk factors, dialysis patients are more susceptible to viralmediated cancers, including human papillomavirus (HPV)-associated cancers such as cervical cancer and carcinoma of the tongue (5). There is also an increased risk for renal cell carcinoma and cancers of urologic transitional cell origin (7,8 -12), likely because of the higher frequency of acquired cystic disease of the kidneys and analgesic abuse (4,5,(7)(8)(9)(10)(11)(12), both recognized risk factors for transitional cell carcinoma of the urologic tract. Epidemiologic studies suggest these cancers may be more common in Asian individuals (7).…”

Section: Cancer Screening In Dialysis Patientsmentioning

confidence: 99%

“…The incidence of acquired cystic disease rises with increasing time on dialysis, and Ͼ50 to 80% of patients are affected after 10 yr (27)(28)(29). Acquired cystic disease is associated with a 1.6 to 7% incidence of renal cell carcinoma (9,27). Because the development of acquired kidney cysts in patients with ESRD corresponds with dialysis duration and because renal cell carcinomas develop in approximately 2% of individuals with acquired cysts, some have argued for routine screening for renal cell carcinoma in patients who are on dialysis for Ͼ3 yr (28).…”

Section: Acquired Cystic Disease and Renal Cell Carcinoma In Dialysismentioning

confidence: 99%

Screening, Diagnosis, and Treatment of Cancer in Long-Term Dialysis Patients

Holley¹

2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Some have suggested that the American Cancer Society guidelines for cancer screening be applied to patients who are on long-term dialysis and have used cancer screening as a means of assessing delivered preventive health care to patients with ESRD. However, cancer screening is effective only when it leads to survival benefit (usually expressed as days of life saved) without incurring high financial costs. Certain cancers such as human papillomavirus-associated cervical and tongue cancer and urologic malignancies are more common among dialysis patients, yet because the expected remaining lifetime of most dialysis patients is shorter than the time lived to develop malignancy, cancer screening in dialysis patients as applied to the general population is ineffective from the perspective of both cost and survival benefit. Cancer screening in dialysis patients is therefore best provided in an individual patient-focused manner. The occurrence, diagnosis, and treatment of cancer as well as issues related to cancer screening in dialysis patients are discussed.

show abstract

“…9 The main cause and duration of end-stage renal disease are also suspected to be a primary determinant of risk for RCC development in the native kidney. 10,11 Some reports indicate that end-stage renal disease patients have approximately 100 times greater risk of RCC than agematched healthy controls. 12 The risk is also expected to increase progressively to the duration of dialysis.…”

Section: Discussionmentioning

confidence: 99%

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Karczewski

Rzymski²,

Karczewski³

2012

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Our study aimed to determine the incidence of de novo renal cell carcinoma in the native kidneys of patients transplanted at our center and to identify possible risk factors. Materials and Methods: We performed a retrospective, single-center cohort study, which included patients transplanted at the District Hospital in Poznan, Poland, during 1994-2011, among whom 836 were selected. Sixty-three patients with confirmed de novo cancer were found. Of those, 11 had renal cell carcinoma in the native kidney (1.3%) and 2 in the transplanted kidney (0.2%). Results: Mean follow-up was 10 ± 3.2 years. Mean age at renal cell carcinoma diagnosis was 52 ± 9.4 years, and mean time from transplant was 3 ± 2.6 years. A statistical analysis showed no significant differences in demographic or clinical characteristics between renal cell carcinoma and noncancer group, except for the prevalence of male sex and smoking in the cancer group (P < .05). Conclusions: Renal cell carcinoma development in the native kidney seems to be an early event, frequently observed within 4 to 5 years after transplant. We believe that kidneys in renal transplant recipients should be routinely screened by ultrasound for early diagnosis.

show abstract

Renal Cell Carcinoma and End Stage Renal Disease

Cited by 68 publications

References 20 publications

Uncommon and recently described renal carcinomas

Uncommon and recently described renal carcinomas

Screening, Diagnosis, and Treatment of Cancer in Long-Term Dialysis Patients

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Contact Info

Product

Resources

About